相关实验视频
Updated: Jun 5, 2025

10:37
Development of Recombinant Proteins to Treat Chronic Pain
Published on: April 11, 2018
9.5K
肠道微生物群:慢性疼痛的调节器和治疗点
Linsen Lou1, Liujing Zhou2, Yongjie Wang3
1School of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, China.
Molecular neurobiology
|December 9, 2024
概括
慢性疼痛影响全球数百万人. 这篇评论探讨了肠道微生物群.
科学领域:
- 微生物学和免疫学
- 神经科学是一个神经科学.
- 胃肠病学 胃肠病学
背景情况:
- 慢性疼痛影响了全球人口的很大一部分,造成了相当大的负担.
- 目前治疗慢性疼痛的方法有局限性,很少能完全治愈.
- 新出现的证据表明,肠道微生物群与慢性疼痛的发展/维持之间存在密切联系.
研究的目的:
- 审查肠道菌群与各种慢性疼痛疾病之间的多方面的关系.
- 探索肠道微生物群影响慢性疼痛的中心和外围机制.
- 确定针对肠道微生物群的慢性疼痛的新型治疗策略.
主要方法:
- 对研究肠道微生物群和慢性疼痛的综合文献综述.
- 对肠道微生物群与大脑之间的通信通路的研究进行分析.
- 检查肠道微生物群在调节与疼痛相关的炎症反应中的作用.
主要成果:
- 肠道微生物群影响各种慢性疼痛类型,包括内脏,神经病,炎症,肌肉骨,偏头痛和癌症疼痛.
- 肠道微生物群通过微生物成分和代谢物与中央神经系统进行通信,影响疼痛感知.
- 肠道微生物群对促炎和抗炎细胞的调节在疼痛调节中起作用.
结论:
- 肠道微生物群是新的慢性疼痛管理策略的一个有希望的目标.
- 治疗干预措施,如益生菌,便微生物移植和天然产品,显示了调节肠道微生物群以缓解慢性疼痛的潜力.
- 对肠-大脑轴和微生物干预的进一步研究可能会导致更有效的缓解疼痛.
相关概念视频
Analgesia and Pain Management
504
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
504
Nociception
27.7K
Nociception—the ability to feel pain—is essential for an organism’s survival and overall well-being. Noxious stimuli such as piercing pain from a sharp object, heat from an open flame, or contact with corrosive chemicals are first detected by sensory receptors, called nociceptors, located on nerve endings. Nociceptors express ion channels that convert noxious stimuli into electrical signals. When these signals reach the brain via sensory neurons, they are perceived as pain.
27.7K
Inflammatory Bowel Disease IV: Pharmacological Management
112
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
112
Irritable Bowel Syndrome I: Introduction
246
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
246
Chronic Bowel Disorders: Introduction
386
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
386
Drugs for Treatment of Constipation-Predominant IBS
134
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
134

